Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 37

1.

Economic benefits of sharing and redistributing influenza vaccines when shortages occurred.

Chen SI.

PLoS One. 2017 Oct 17;12(10):e0186418. doi: 10.1371/journal.pone.0186418. eCollection 2017.

2.

Protecting our patients by protecting ourselves: An analysis of the personal influenza immunization rate of Ontario community pharmacists.

Ziegler B, Alsabbagh W, Houle S, Wenger L, Church D, Waite N.

Can Pharm J (Ott). 2016 Jul;149(4):246-55. doi: 10.1177/1715163516651630. Epub 2016 May 27.

3.

Cost-effectiveness analysis of the direct and indirect impact of intranasal live attenuated influenza vaccination strategies in children: alternative country profiles.

Gibson E, Begum N, Martinón-Torres F, Safadi MA, Sackeyfio A, Hackett J, Rajaram S.

J Mark Access Health Policy. 2016 Jun 28;4. doi: 10.3402/jmahp.v4.31205. eCollection 2016.

4.

Recommended immunization schedules for adults: Clinical practice guidelines by the Escmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid).

Esposito S, Bonanni P, Maggi S, Tan L, Ansaldi F, Lopalco PL, Dagan R, Michel JP, van Damme P, Gaillat J, Prymula R, Vesikari T, Mussini C, Frank U, Osterhaus A, Celentano LP, Rossi M, Guercio V, Gavazzi G.

Hum Vaccin Immunother. 2016 Jul 2;12(7):1777-94. doi: 10.1080/21645515.2016.1150396. Epub 2016 May 2. Review.

5.

Evaluation of Antihemagglutinin and Antineuraminidase Antibodies as Correlates of Protection in an Influenza A/H1N1 Virus Healthy Human Challenge Model.

Memoli MJ, Shaw PA, Han A, Czajkowski L, Reed S, Athota R, Bristol T, Fargis S, Risos K, Powers JH, Davey RT Jr, Taubenberger JK.

MBio. 2016 Apr 19;7(2):e00417-16. doi: 10.1128/mBio.00417-16.

6.

Cost-effectiveness analysis of antiviral treatment in the management of seasonal influenza A: point-of-care rapid test versus clinical judgment.

Nshimyumukiza L, Douville X, Fournier D, Duplantie J, Daher RK, Charlebois I, Longtin J, Papenburg J, Guay M, Boissinot M, Bergeron MG, Boudreau D, Gagné C, Rousseau F, Reinharz D.

Influenza Other Respir Viruses. 2016 Mar;10(2):113-21. doi: 10.1111/irv.12359. Epub 2016 Jan 29.

7.

A Novel Dynamic Model for Health Economic Analysis of Influenza Vaccination in the Elderly.

Mullikin M, Tan L, Jansen JP, Van Ranst M, Farkas N, Petri E.

Infect Dis Ther. 2015 Dec;4(4):459-87. doi: 10.1007/s40121-015-0076-8. Epub 2015 Sep 9. Erratum in: Infect Dis Ther. 2015 Dec;4(4):489-90.

8.

Self-recognition drives the preferential accumulation of promiscuous CD4(+) T-cells in aged mice.

Deshpande NR, Parrish HL, Kuhns MS.

Elife. 2015 Jul 14;4:e05949. doi: 10.7554/eLife.05949.

9.

Respiratory Infections in the U.S. Military: Recent Experience and Control.

Sanchez JL, Cooper MJ, Myers CA, Cummings JF, Vest KG, Russell KL, Sanchez JL, Hiser MJ, Gaydos CA.

Clin Microbiol Rev. 2015 Jul;28(3):743-800. doi: 10.1128/CMR.00039-14. Review.

10.

Construction and Immunogenicity Evaluation of Recombinant Influenza A Viruses Containing Chimeric Hemagglutinin Genes Derived from Genetically Divergent Influenza A H1N1 Subtype Viruses.

McCormick K, Jiang Z, Zhu L, Lawson SR, Langenhorst R, Ransburgh R, Brunick C, Tracy MC, Hurtig HR, Mabee LM, Mingo M, Li Y, Webby RJ, Huber VC, Fang Y.

PLoS One. 2015 Jun 10;10(6):e0127649. doi: 10.1371/journal.pone.0127649. eCollection 2015.

11.

Safety and immunogenicity of influenza whole inactivated virus vaccines: A phase I randomized clinical trial.

van Boxtel RA, Verdijk P, de Boer OJ, van Riet E, Mensinga TT, Luytjes W.

Hum Vaccin Immunother. 2015;11(4):983-90. doi: 10.1080/21645515.2015.1012004.

12.

Heterosubtypic antibodies to influenza A virus have limited activity against cell-bound virus but are not impaired by strain-specific serum antibodies.

Wyrzucki A, Bianchi M, Kohler I, Steck M, Hangartner L.

J Virol. 2015 Mar;89(6):3136-44. doi: 10.1128/JVI.03069-14. Epub 2014 Dec 31.

13.

Infants and the seasonal influenza vaccine. A global perspective on safety, effectiveness, and alternate forms of protection.

Moriarty LF, Omer SB.

Hum Vaccin Immunother. 2014;10(9):2721-8. doi: 10.4161/hv.29669. Review.

14.

Animal models for influenza viruses: implications for universal vaccine development.

Margine I, Krammer F.

Pathogens. 2014 Oct 21;3(4):845-74. doi: 10.3390/pathogens3040845. Review.

15.

Influenza vaccines: unmet needs and recent developments.

Noh JY, Kim WJ.

Infect Chemother. 2013 Dec;45(4):375-86. doi: 10.3947/ic.2013.45.4.375. Epub 2013 Dec 27. Review.

16.

Coverage and parental perceptions of influenza vaccination among parents of children aged 6 to 23 months in Hong Kong.

Lau JT, Mo PK, Cai YS, Tsui HY, Choi KC.

BMC Public Health. 2013 Oct 30;13:1026. doi: 10.1186/1471-2458-13-1026.

17.

Effectiveness of seasonal influenza vaccine against clinically diagnosed influenza over 2 consecutive seasons in children in Guangzhou, China: a matched case-control study.

He Q, Xu J, Chen X, Lu J, Li K, Li Z, Wang M, Yang Q, Dong Z, Liu X, Wu X, Hu W, Zhang D, Lv J, Nie J, Zhu W, Fu C.

Hum Vaccin Immunother. 2013 Aug;9(8):1720-4. doi: 10.4161/hv.24980. Epub 2013 Jun 3.

18.

Cloned defective interfering influenza virus protects ferrets from pandemic 2009 influenza A virus and allows protective immunity to be established.

Dimmock NJ, Dove BK, Scott PD, Meng B, Taylor I, Cheung L, Hallis B, Marriott AC, Carroll MW, Easton AJ.

PLoS One. 2012;7(12):e49394. doi: 10.1371/journal.pone.0049394. Epub 2012 Dec 12.

19.

Residual baculovirus in insect cell-derived influenza virus-like particle preparations enhances immunogenicity.

Margine I, Martinez-Gil L, Chou YY, Krammer F.

PLoS One. 2012;7(12):e51559. doi: 10.1371/journal.pone.0051559. Epub 2012 Dec 7.

20.

Comparison of the protection of ferrets against pandemic 2009 influenza A virus (H1N1) by 244 DI influenza virus and oseltamivir.

Dimmock NJ, Dove BK, Meng B, Scott PD, Taylor I, Cheung L, Hallis B, Marriott AC, Carroll MW, Easton AJ.

Antiviral Res. 2012 Dec;96(3):376-85. doi: 10.1016/j.antiviral.2012.09.017. Epub 2012 Oct 4.

Supplemental Content

Support Center